We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

93 hedge funds and large institutions have $457M invested in G1 Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 17

3% more call options, than puts

Call options by funds: $183K | Put options by funds: $178K

0% more funds holding

Funds holding: 93 → 93 (0)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

13% less capital invested

Capital invested by funds: $525M → $457M (-$68.8M)

Holders
93
Holders Change
–
Holders Change %
0%
% of All Funds
2.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
41
Reduced
17
Closed
14
Calls
$183K
Puts
$178K
Net Calls
+$5K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$16.4M
2
RCM
RA Capital Management
Massachusetts
+$6.89M
3
VOYA Investment Management
VOYA Investment Management
Georgia
+$4.57M
4
Bank of America
Bank of America
North Carolina
+$3.65M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.35M

Top Sellers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
-$21.3M
2
CAM
Cormorant Asset Management
Massachusetts
-$19M
3
Marshall Wace
Marshall Wace
United Kingdom
-$5.72M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.97M
5
Capital International Investors
Capital International Investors
California
-$2.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$2.11M – – –
Goldman Sachs
27
Goldman Sachs
New York
$1.91M +$485K +25,585 +29%
IBT
28
International Biotechnology Trust
United Kingdom
$1.63M +$1.87M +98,482 New
AA
29
ALPS Advisors
Colorado
$1.49M +$73.7K +3,885 +5%
Marshall Wace
30
Marshall Wace
United Kingdom
$1.41M -$5.72M -301,586 -78%
Capital World Investors
31
Capital World Investors
California
$1.4M -$21.3M -1,122,600 -93%
USAA
32
United Services Automobile Association
Texas
$1.37M +$270K +14,229 +21%
Renaissance Technologies
33
Renaissance Technologies
New York
$1.17M +$1.34M +70,700 New
Invesco
34
Invesco
Georgia
$1.17M +$708K +37,307 +113%
Ameriprise
35
Ameriprise
Minnesota
$1.02M +$517K +27,278 +80%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$925K +$1.06M +55,719 New
ARTA
37
A.R.T. Advisors
New York
$914K +$321K +16,913 +44%
TA
38
Teachers Advisors
New York
$827K +$92.7K +4,886 +11%
Swiss National Bank
39
Swiss National Bank
Switzerland
$732K +$108K +5,700 +15%
TD Asset Management
40
TD Asset Management
Ontario, Canada
$712K +$7.59K +400 +0.9%
DekaBank Deutsche Girozentrale
41
DekaBank Deutsche Girozentrale
Germany
$691K +$39.8K +2,100 +22%
CSS
42
Cubist Systematic Strategies
Connecticut
$649K +$252K +13,305 +52%
S
43
SignatureFD
Georgia
$630K – – –
SCA
44
Secor Capital Advisors
New York
$618K +$87.5K +4,614 +14%
TCIM
45
TIAA CREF Investment Management
New York
$608K +$83.1K +4,381 +14%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$592K – – –
Allianz Asset Management
47
Allianz Asset Management
Germany
$588K +$419K +22,083 +166%
BWA
48
BDO Wealth Advisors
Florida
$585K +$668K +35,234 New
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$550K -$281K -14,825 -31%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$533K +$60.7K +3,200 +11%
1
2
3 4 5

GTHX Hedge Fund Activity: Q1 2019 in Review

93 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2019, worth a combined $457M — down 13% from $525M a quarter earlier.

Fund positioning in GTHX was balanced in Q1 2019: 14 funds opened new positions, 14 closed out, 41 added to existing stakes and 17 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $16.4M. The largest seller was Capital World Investors, cutting an estimated $21.3M.

  • 93 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $457M of G1 Therapeutics, Inc. Common Stock stock for Q1 2019, down 13% quarter-over-quarter.
  • 14 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2019 and 14 closed out, a net change of 0 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2019 was Wellington Management Group, an estimated $16.4M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2019 was Capital World Investors, an estimated $21.3M sold.

Based on aggregated 13F filings for Q1 2019.